(Q36192744)

12 August 2017

1 reference

title

A pharmacogeneticist's look at drug effects and the drug development process: an overview (English)

1 reference

12 August 2017

Werner Kalow

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

1299-1303

1 reference

Clinical consequences of cytochrome P450 2C9 polymorphisms

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Alcohol dehydrogenase and alcohol dependence: variation in genotype-associated risk between populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Decreasing smoking behaviour and risk through CYP2A6 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Gene expression induced by drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

SNP discovery and typing technologies for pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Pharmacogenetics and drug development: the path to safer and more effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Applications of pharmacogenetics to drug development: the Glaxo Wellcome experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Target discovery and validation in the post-genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Pharmacogenetics and future drug development and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

Clinical trials in the genomic era: effects of protective genotypes on sample size and duration of trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.8.1299

10.1517/14656566.6.8.1299

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference